150 related articles for article (PubMed ID: 22153224)
21. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
[TBL] [Abstract][Full Text] [Related]
22. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
23. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
[TBL] [Abstract][Full Text] [Related]
24. Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.
Sandoval-Ramirez JL; Mata-Marín JA; Huerta García G; Gaytán-Martínez JE
J Infect Dev Ctries; 2015 Mar; 9(3):267-73. PubMed ID: 25771464
[TBL] [Abstract][Full Text] [Related]
25. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
26. [The effect of cryoglobulinemia on the antiviral therapy in patients with chronic hepatitis C].
Fan XH; Wang LF; Liu LC; Yao Y; Shan Y; Lu HY; Wu CH; Xu XY; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):721-5. PubMed ID: 22409840
[TBL] [Abstract][Full Text] [Related]
27. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
[TBL] [Abstract][Full Text] [Related]
28. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
[TBL] [Abstract][Full Text] [Related]
29. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
Sherman M; Yoshida EM; Deschenes M; Krajden M; Bain VG; Peltekian K; Anderson F; Kaita K; Simonyi S; Balshaw R; Lee SS;
Gut; 2006 Nov; 55(11):1631-8. PubMed ID: 16709661
[TBL] [Abstract][Full Text] [Related]
30. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
Dogan UB; Akin MS; Yalaki S
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1317-20. PubMed ID: 23680912
[TBL] [Abstract][Full Text] [Related]
31. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
32. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
33. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
Marcellin P; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Serfaty L; De Backer K; Van Heeswijk R; Luo D; Picchio G; Beumont M
Gastroenterology; 2011 Feb; 140(2):459-468.e1; quiz e14. PubMed ID: 21034744
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
[TBL] [Abstract][Full Text] [Related]
35. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
[TBL] [Abstract][Full Text] [Related]
36. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
37. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
38. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
39. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.
Lodato F; Berardi S; Gramenzi A; Mazzella G; Lenzi M; Morelli MC; Tame MR; Piscaglia F; Andreone P; ; Ballardini G; Bernardi M; Bianchi FB; Biselli M; Bolondi L; Cescon M; Colecchia A; D'Errico A; Del Gaudio M; Ercolani G; Grazi GL; Grigioni W; Lorenzini S; Pinna AD; Ravaioli M; Roda E; Sama C; Vivarelli M
Aliment Pharmacol Ther; 2008 Aug; 28(4):450-7. PubMed ID: 18549463
[TBL] [Abstract][Full Text] [Related]
40. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
